vs
Side-by-side financial comparison of Alset Inc. (AEI) and Mind Medicine (MindMed) Inc. (DFTX). Click either name above to swap in a different company.
Alset Inc. is the larger business by last-quarter revenue ($1.3M vs $906.0K, roughly 1.4× Mind Medicine (MindMed) Inc.). On growth, Mind Medicine (MindMed) Inc. posted the faster year-over-year revenue change (-16.1% vs -85.4%).
Alset Global GmbH is an Austrian technology and engineering company based in Graz that specialises in hydrogen-based clean mobility products. Alset Global is known for developing a Hybrid Hydrogen internal combustion engine that can run on either pure petrol, pure hydrogen or a combination of both. This technology offers a sustainable and clean alternative to petrol-based internal combustion engines. The technology has been developed to create an alternative technology to meet new emission ta...
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
AEI vs DFTX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2023
| Metric | | |
|---|---|---|
| Revenue | $1.3M | $906.0K |
| Net Profit | — | $-23.9M |
| Gross Margin | 35.2% | — |
| Operating Margin | — | -2450.8% |
| Net Margin | — | -2634.0% |
| Revenue YoY | -85.4% | -16.1% |
| Net Profit YoY | -1491.5% | -386.7% |
| EPS (diluted) | — | $-0.58 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.3M | — | ||
| Q3 25 | $998.8K | — | ||
| Q2 25 | $1.1M | — | ||
| Q1 25 | $1.1M | — | ||
| Q4 24 | $8.9M | — | ||
| Q3 24 | $5.0M | — | ||
| Q2 24 | $1.1M | — | ||
| Q1 24 | $6.1M | — |
| Q4 25 | — | — | ||
| Q3 25 | $1.5M | — | ||
| Q2 25 | $-8.2M | — | ||
| Q1 25 | $-8.3M | — | ||
| Q4 24 | $2.3M | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $-1.2M | — | ||
| Q1 24 | $-6.8M | — |
| Q4 25 | 35.2% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 23.3% | — | ||
| Q1 25 | 27.2% | — | ||
| Q4 24 | 51.4% | — | ||
| Q3 24 | 40.5% | — | ||
| Q2 24 | 26.4% | — | ||
| Q1 24 | 23.5% | — |
| Q4 25 | — | — | ||
| Q3 25 | -258.2% | — | ||
| Q2 25 | -250.7% | — | ||
| Q1 25 | -368.1% | — | ||
| Q4 24 | 21.5% | — | ||
| Q3 24 | -19.4% | — | ||
| Q2 24 | -249.3% | — | ||
| Q1 24 | -37.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | 151.4% | — | ||
| Q2 25 | -748.1% | — | ||
| Q1 25 | -780.1% | — | ||
| Q4 24 | 26.0% | — | ||
| Q3 24 | 34.6% | — | ||
| Q2 24 | -109.9% | — | ||
| Q1 24 | -111.2% | — |
| Q4 25 | — | — | ||
| Q3 25 | $0.05 | — | ||
| Q2 25 | $-0.71 | — | ||
| Q1 25 | $-0.78 | — | ||
| Q4 24 | $0.24 | — | ||
| Q3 24 | $0.19 | — | ||
| Q2 24 | $-0.13 | — | ||
| Q1 24 | $-0.73 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $25.2M | $99.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $121.1M | $78.1M |
| Total Assets | $136.6M | $124.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $25.2M | — | ||
| Q3 25 | $25.5M | — | ||
| Q2 25 | $25.6M | — | ||
| Q1 25 | $25.2M | — | ||
| Q4 24 | $27.2M | — | ||
| Q3 24 | $16.7M | — | ||
| Q2 24 | $18.9M | — | ||
| Q1 24 | $23.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $116.5K | — | ||
| Q4 24 | $123.1K | — | ||
| Q3 24 | $137.9K | — | ||
| Q2 24 | $137.8K | — | ||
| Q1 24 | $145.8K | — |
| Q4 25 | $121.1M | — | ||
| Q3 25 | $155.7M | — | ||
| Q2 25 | $72.8M | — | ||
| Q1 25 | $76.4M | — | ||
| Q4 24 | $81.3M | — | ||
| Q3 24 | $84.2M | — | ||
| Q2 24 | $79.4M | — | ||
| Q1 24 | $81.7M | — |
| Q4 25 | $136.6M | — | ||
| Q3 25 | $169.1M | — | ||
| Q2 25 | $86.0M | — | ||
| Q1 25 | $90.5M | — | ||
| Q4 24 | $96.8M | — | ||
| Q3 24 | $98.8M | — | ||
| Q2 24 | $93.5M | — | ||
| Q1 24 | $96.7M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-5.9M | $-20.6M |
| Free Cash FlowOCF − Capex | $-6.1M | — |
| FCF MarginFCF / Revenue | -467.7% | — |
| Capex IntensityCapex / Revenue | 13.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-11.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-5.9M | — | ||
| Q3 25 | $883.4K | — | ||
| Q2 25 | $-2.6M | — | ||
| Q1 25 | $-3.8M | — | ||
| Q4 24 | $5.2M | — | ||
| Q3 24 | $-2.9M | — | ||
| Q2 24 | $-4.4M | — | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | $-6.1M | — | ||
| Q3 25 | $822.4K | — | ||
| Q2 25 | $-2.7M | — | ||
| Q1 25 | $-3.8M | — | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $-2.9M | — | ||
| Q2 24 | $-4.4M | — | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | -467.7% | — | ||
| Q3 25 | 82.3% | — | ||
| Q2 25 | -245.9% | — | ||
| Q1 25 | -357.3% | — | ||
| Q4 24 | 56.5% | — | ||
| Q3 24 | -58.2% | — | ||
| Q2 24 | -392.3% | — | ||
| Q1 24 | -24.8% | — |
| Q4 25 | 13.4% | — | ||
| Q3 25 | 6.1% | — | ||
| Q2 25 | 7.6% | — | ||
| Q1 25 | 5.7% | — | ||
| Q4 24 | 1.1% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 3.0% | — | ||
| Q1 24 | 0.0% | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.58× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.22× | — | ||
| Q3 24 | -1.66× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
